Autologous Cellular Immunotherapy
- Name
- Autologous Cellular Immunotherapy
- Accession Number
- DBCAT003475
- Description
Not Available
- Drugs
Drug Drug Description Sipuleucel-T An autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Idecabtagene vicleucel An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. Rocapuldencel-T Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer). Lifileucel An autologous T cell immunotherapy used to treat unresectable or metastatic melanoma in previously treated adults. - Drugs & Drug Targets
Drug Target Type Sipuleucel-T Prostatic acid phosphatase target Idecabtagene vicleucel Tumor necrosis factor receptor superfamily member 17 target